Black Di­a­mond rais­es an­oth­er $85M to bring new onco­gene ap­proach in­to clin­ic

Near­ly a year af­ter rais­ing $85 mil­lion from in­vestors, Black Di­a­mond Ther­a­peu­tics has raised an­oth­er $85 mil­lion to help push its al­losteric ther­a­pies in­to the clin­ic in the next few months. The Se­ries C round was led by Box­er Cap­i­tal.

Black Di­a­mond launched last De­cem­ber as the first com­pa­ny to come out of Ver­sant’s Ridge­line dis­cov­ery en­gine in Basel. They had two for­mer de­vel­op­ers of the can­cer drug Tarce­va as co-founders in David Ep­stein and Eliz­a­beth Buck and a rel­a­tive­ly new ap­proach to on­col­o­gy. With­in a month of their full launch, they al­so had $105 mil­lion in back­ing.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN